多瑞醫藥(301075.SZ):擬成立控股子公司十堰佳瑞和 建設地道中藥材初加工生產基地
格隆匯3月3日丨多瑞醫藥(301075.SZ)公佈,公司與關聯方湖北天濟藥業有限公司(簡稱“湖北天濟”)和非關聯方十堰鄂陝川中藥材有限公司(簡稱“十堰鄂陝川”)共同出資設立子公司十堰佳瑞和中藥材有限公司(簡稱“十堰佳瑞和”)。多瑞醫藥、湖北天濟、十堰鄂陝川認繳出資額分別為153萬元、30萬元及117萬元,認繳比例分別為51%、10%及39%。
公司子公司十堰佳瑞和依託十堰市房縣優質的中藥材及地標產品資源,以房縣及神農架為中心輻射秦巴山區域,建設地道中藥材初加工生產基地,致力於打造成為中藥材種植、採購、加工、銷售為一體的特色企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.